China Biologic Products Holdings Receivables

China Biologic Products Holdings (CBPO) currently reports a receivables of $150M as of December 2020. That compares with $100M in the prior-year period — up 51.7% year over year. Use the charts on this page to explore China Biologic Products Holdings's receivables history and peer comparisons.

China Biologic Products Holdings's receivables increased from $100M to $150M — a 51.7% year-over-year increase (period ending December 2020). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

China Biologic Products Holdings reported $150M in receivables as of December 2020. That compares with $100M in the prior-year period — up 51.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $150M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for China Biologic Products Holdings, and consider following CBPO for alerts when major investors trade the stock.

China Biologic Products Holdings is classified in the Healthcare sector. On receivables, it currently shows $150M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CBPO with unrelated industries.